Abstract
Most populated corners of the planet have been exposed to SARS-CoV-2, the coronavirus behind the COVID-19 pandemic. We examined the progression of COVID-19 in four island nations that fared well over the first three months of the pandemic: New Zealand, Australia, Iceland, and Taiwan. Using Bayesian phylodynamic methods, we estimated the effective reproduction number of COVID-19 in the four islands as 1–1.4 during early stages of the pandemic, and show that it declined below 1 as human movement was restricted. Our reconstruction of COVID-19’s phylogenetic history indicated that this disease was introduced many times into each island, and that introductions slowed down markedly when the borders closed. Finally, we found that New Zealand clusters identified via standard health surveillance largely agreed with those defined by genomic data. Our findings can assist public health decisions in countries with circulating SARS-CoV-2, and support efforts to mitigate any second waves or future epidemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We wish to thank all of the authors who have shared their genomic data on GISAID. A full table outlining the originating and submitting labs is included as a supplementary file. This research was supported by a contract from the Health Research Council of New Zealand (20/1018), a COVID-19 Innovation Acceleration Fund (grant CIAF-0470) from the Ministry of Business, Innovation & Employment's Research Infrastructure (MBIE), and Marsden grants 16-UOA-277 and 18-UOA-096 from the Royal Society of New Zealand. Genome sequencing was partially funded by New Zealand Ministry of Health. Finally, we wish to acknowledge the use of New Zealand eScience Infrastructure (NeSI) high performance computing facilities, funded jointly by NeSI's collaborator institutions and through the MBIE's Research Infrastructure program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The genomic data was obtained by the Institute of Environmental Science and Research (ESR). Under contract of the Ministry of Health New Zealand, ESR holds ethical approval to conduct genomic sequencing for disease surveillance.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon publication
